-The Business Standard The recent US-India friction over trade is being driven by Big Pharma Apart from the deterioration of the business environment generally, which impacts both domestic and foreign investors, retrospective taxation has figured most prominently in the media as the principal cause of growing scepticism among foreign investors. Entirely missing from the discourse has been an equally potent factor with wholly foreign origins: the hijacking of the economic policy...

-The Indian Express India's role in pharmaceutical patent wars has broadened access to healthcare. Recently, there were rumours that the United States Trade Representative (USTR) was getting ready to announce "trade enforcement actions" or sanctions against India over its Intellectual Property Rights regime. The Obama administration has been under pressure from the US Chamber of Commerce and lobby groups, like the Pharmaceutical Research and Manufacturers of America, to take a tough stance...

-Down to Earth Japan's Sapporo brewery patents Indian barley gene without giving benefit to farmers Ballia district, the easternmost part of Uttar Pradesh, is a flood-prone area that extends towards Bihar from the confluence of the Ganga and the Ghaghra. Over decades, its farmers, mostly marginal and small, have been cultivating barley, exchanging its seeds, improving the varieties and giving these to a government project to cull the best of the lot....

-Press Information Bureau (Ministry of Tribal Affairs) Government has disposed of 31, 06,690 claims by the end of Dec-2013 out of 36,54,420 claims filed under Scheduled Tribes and other Traditional Forest Dwellers (Recognition of Forest Rights) Act -2006, commonly known as Forest Rights Act (FRA). This is 85.01% of the total claims filed under the Act. Out of the claims disposed off, 14,18,078 titles (13,95,647 individual titles and 22,431...

-The Hindu Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions "are not about access to medicine." In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that...